Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review
ABSTRACT Hypoxia‐inducible factor prolyl hydroxylase (HIF‐PH) inhibitors are a new class of agents for the treatment of anemia in chronic kidney disease (CKD). Unlike traditional treatments such as erythropoiesis‐stimulating agents (ESAs), HIF‐PH inhibitors are orally administered drugs and may incr...
Saved in:
Main Authors: | Wei Zhang, Yan Li, Ji‐Guang Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-12-01
|
Series: | The Journal of Clinical Hypertension |
Subjects: | |
Online Access: | https://doi.org/10.1111/jch.14924 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review
by: Yousuf Abdulkarim Waheed, et al.
Published: (2024-12-01) -
Endothelial Cell‐Specific Prolyl Hydroxylase‐2 Deficiency Augments Angiotensin II–Induced Arterial Stiffness and Cardiac Pericyte Recruitment in Mice
by: Bo Liu, et al.
Published: (2024-08-01) -
Efficacy of Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitors in Renal Anemia: Enhancing Erythropoiesis and Long-Term Outcomes in Patients with Chronic Kidney Disease
by: Yukina Yoshida, et al.
Published: (2024-12-01) -
Nanoscale Systems for Local Activation of Hypoxia-Inducible Factor-1 Alpha: A New Approach in Diabetic Wound Management
by: Saber S, et al.
Published: (2024-12-01) -
Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat
by: Serina Kita, et al.
Published: (2024-09-01)